TIL’s lymphocyte expression in patient with Colorectal cancer
-
Published:2022-12-30
Issue:2
Volume:12
Page:62-66
-
ISSN:2083-1617
-
Container-title:Progress in Health Sciences
-
language:
-
Short-container-title:Prog Health Sci
Affiliation:
1. Medical University of Warsaw, Poland
Abstract
Purpose: Colorectal cancer cells are infiltrated by different types of immune cells. They are scattered throughout the medulla, stroma, and glands of the tumor, as well as in the invasive margin and in organized lymphoid follicles distant from the cancerous lesion. The aim of the study was to presence of CD8+ T lymphocyte infiltration in the tumor and its front in correlation with clinicopathological parameters.
Materials and Methods: The study included a group 62 of patients operated on due to colorectal cancer. The histopathological results of the patients were analyzed, including the assessment of the expression of CD8+ T lymphocytes in the main mass of the tumor and its front, and an analysis of correlation with the patient’s age, sex, histological malignancy stage, presence of metastases to lymph nodes and distant metastases was performed.
Results: Statistical significance was demonstrated for the correlation between the differentiation of TCD8+ infiltration in the invasion front and the presence of distant metastases (p = 0.041). Statistical significance was demonstrated for the correlation between the differentiation of TCD8+ infiltration in the invasion front and the depth of tumor infiltration (p = 0.042).
Conclusions: The immune response expressed by CD8+ T lymphocyte infiltration increases with the depth of tumor infiltration. An immune response expressed by a strong expression of CD8+ T lymphocytes may be an indicator of the absence of distant metastases.
Publisher
Index Copernicus
Reference16 articles.
1. Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther. 2008;8: 561–72. 2. Galon J, Mlecnik B, indea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chou-chane L, Ohashi PS, Hafezi-Ba khtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199-209. 3. Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22(2):215-22. 4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 Sep 29; 313(5795):1960-4. 5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor esca- pe. Nat Immunol. 2002;3(11):991–8.
|
|